About me
Anthony P. Green, Ph.D., chief scientific officer for Ben Franklin Technology Partners, has over thirty years of experience in the biotechnology industry with a track record of success in developing and commercializing cutting-edge technologies from immunodiagnostics to monoclonal antibodies to gene vaccines/gene therapy. Since 2006, he has advocated for an innovation agenda and has engaged with the region’s research institutions, start-up community, and corporations to gain insights into future trends and opportunities.
Dr. Green created Ben Franklin’s earliest seed funding program, investing $6M in 125 companies and more than $80M in follow-on funding. With PACT, Dr. Green created Mentor Connect, the Philadelphia node of the MIT Venture Mentoring Service, and led Ben Franklin’s service and prototyping programs, FabNet and PRIMA. Dr. Green was instrumental creating the Temple University co-investment program—the first program of its kind in the country and led new public/private commercialization models in life sciences, medtech, digital health, advanced textiles, advanced manufacturing, energy, IoT, and nanotechnology.
Dr. Green is a member of the oversight and advisory committees of Penn Health Tech, the Coulter-Drexel Translational Research Partnership, UPenn’s Singh Center for Nanotechnology, Children’s Hospital’s Pediatric Medical Device Consortium, and a New Age Industries Board of Directors.
Dr. Green’s 30+ years of experience in the biotechnology industry includes Centocor, BD, and Puresyn, focused on the development and commercialization of immunodiagnostic, monoclonal antibody, and gene transfer technologies. Dr. Green earned his Sc.B in Immunology, with Honors, from Brown University and his Ph.D. in Microbiology and Immunology from Temple University School of Medicine.
